Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2014-10-09 Earnings Release
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Information financière du troisième trimestre
Earnings Release Classification · 98% confidence The document provides a summary of financial results (Revenus and Trésorerie) for the 3rd quarter and the first 9 months ending September 30, 2014. It includes key figures, a breakdown of revenues in a table format, commentary from management, and a notice about the next financial publication date. This structure—a concise announcement of period-specific financial performance highlights—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), as it focuses on key metrics and commentary rather than full financial statements, and it explicitly states the data is 'non auditées' (unaudited). 9M 2014
2014-10-09 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 99% confidence The document is a press release announcing the appointment of three new directors to the management team (Head of Business Development, Head of Bio-informatics/IT, and Head of Human Resources). This directly relates to changes in senior management personnel. Based on the provided definitions, the most appropriate classification is 'Board/Management Information' (MANG). It is not an earnings release (ER), a full annual report (10-K), or a proxy statement (PSI). The document length (7024 chars) is substantial enough that it is the primary announcement, not just a brief notification of publication (RPA/RNS).
2014-09-11 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 99% confidence The document is a press release announcing the appointment of three new directors to the management team (Business Development, Bio-informatics/IT, and Human Resources). This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management. The text is structured as a formal corporate announcement, not a detailed financial report (like 10-K or IR) or a transcript (CT).
2014-09-11 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Genomic Vision has been selected to join the CAC® Mid & Small index, effective September 22, 2014. This type of announcement, which details a change in stock market listing status or index inclusion, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate action categories (like DIV, CAP, SHA). It is a general corporate update related to market visibility and stock performance. Since it is a specific, non-standard regulatory announcement that doesn't match the other defined categories (AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, POS), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements.
2014-09-08 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Genomic Vision has been selected to join the CAC® Mid & Small index, effective September 22, 2014. This announcement relates to the company's stock listing status and market capitalization, which impacts its capital structure and investor visibility. This type of announcement, concerning stock market inclusion/exclusion or significant capital structure events, best fits the 'Capital/Financing Update' (CAP) category, as it directly affects how the company is traded and valued in the market, although it is not a direct financing event like issuing new shares. However, given the options, it is a significant corporate action announcement. It is not an Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like a 10-K. Since it is an announcement about market status and index inclusion, which is a form of corporate finance/capital structure news, CAP is the most appropriate fit among the specific codes provided, as it is more specific than the general 'RNS' fallback. The document length (5147 chars) is substantial enough to be the primary announcement itself, not just a brief notice of publication.
2014-09-08 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated August 25, 2014, announcing that Genomic Vision presented the first results of its HPV detection test development program at the HPV 2014 conference. It details scientific findings related to molecular combing technology and HPV DNA integration. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement of research/development progress and presentation of data, which fits best under the general category of Investor Relations or a specific announcement that doesn't fit other codes. Since it is a specific announcement about company activity (R&D presentation) and not a standard financial report, and it is not a management change (MANG), director dealing (DIRS), or capital event (CAP), it is best classified as a general Regulatory Filing (RNS) as a fallback for specific, non-standard corporate updates, or potentially Investor Presentation (IP) if it were the presentation itself, but this is a press release *about* the presentation. Given the options, RNS serves as the most appropriate catch-all for this type of specific, non-financial-reporting corporate news release.
2014-08-25 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.